Merck & Co., Inc. Disposal Group, Including Discontinued Operation, General and Administrative Expense
Merck & Co., Inc. (MRK) reported Disposal Group, Including Discontinued Operation, General and Administrative Expense of $877.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense · last filed 2024-02-26
- Merck & Co., Inc. disposal group, including discontinued operation, general and administrative expense for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. disposal group, including discontinued operation, general and administrative expense for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. disposal group, including discontinued operation, general and administrative expense for the quarter ending 2021-06-30 was $431.00M, a 47.10% increase year-over-year.
- Merck & Co., Inc. disposal group, including discontinued operation, general and administrative expense for the quarter ending 2021-03-31 was $446.00M.
- Merck & Co., Inc. disposal group, including discontinued operation, general and administrative expense for fiscal 2021 was $877.00M, a 42.04% decline from fiscal 2020.
- Merck & Co., Inc. disposal group, including discontinued operation, general and administrative expense for fiscal 2020 was $1.51B, a 30.43% increase from fiscal 2019.
- Merck & Co., Inc. disposal group, including discontinued operation, general and administrative expense for fiscal 2019 was $1.16B.
| Period end | Disposal Group, Including Discontinued Operation, General and Administrative Expense 3 month | Disposal Group, Including Discontinued Operation, General and Administrative Expense 6 month | Disposal Group, Including Discontinued Operation, General and Administrative Expense 9 month | Disposal Group, Including Discontinued Operation, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $0.00 derived: sum of 2 quarters · filed 2024-02-26 | $431.00M derived: sum of 3 quarters · filed 2024-02-26 | $877.00M 10-K · filed 2024-02-26 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $431.00M derived: sum of 2 quarters · filed 2022-11-03 | $877.00M 10-Q · filed 2022-11-03 | $1.34B derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | $431.00M 10-Q · filed 2022-08-05 | $877.00M 10-Q · filed 2022-08-05 | $1.34B derived: sum of 3 quarters · filed 2023-02-24 | $1.73B derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-03-31 | $446.00M 10-Q · filed 2022-05-05 | $913.00M derived: sum of 2 quarters · filed 2023-02-24 | $1.30B derived: sum of 3 quarters · filed 2023-02-24 | $1.60B derived: sum of 4 quarters · filed 2023-02-24 |
| 2020-12-31 | $467.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $857.00M derived: sum of 2 quarters · filed 2023-02-24 | $1.15B derived: sum of 3 quarters · filed 2023-02-24 | $1.51B 10-K · filed 2023-02-24 |
| 2020-09-30 | $390.00M 10-Q · filed 2021-11-05 | $683.00M derived: sum of 2 quarters · filed 2021-11-05 | $1.05B 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $293.00M 10-Q · filed 2021-08-09 | $657.00M 10-Q · filed 2021-08-09 | ||
| 2019-12-31 | $1.16B 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |